8-K filing — Allarity Therapeutics, Inc. (ALLR)
Filed: 2026-08-14 AccNo: 0001213900-26-090183 Size: 303 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Allarity Therapeutics Secures CLIA For In-House Lab
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Allarity Therapeutics Q2 EPS $(0.21) Beats $(0.25) Estimate
Allarity Therapeutics (NASDAQ:ALLR) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.25) by 16 percent. This is a 40 percent decrease over losses of $(0.15) per share from
Allarity Therapeutics Receives U.S. Patent And Trademark Office Patent For Its Drug Response Predictor Companion Diagnostic